Dow, Colorcon Add Excipients to Alliance Offerings

News
Article

Dow and Colorcon extend and broaden the scope of the Controlled Release Alliance.

Colorcon and The Dow Chemical Company have agreed to broaden their existing Controlled Release Alliance to include Dow’s advanced technology-based pharmaceutical excipients, effective January 1, 2017. The Alliance, originally announced in July 2007, currently provides controlled-release technologies from Dow Pharma & Food Solutions, a business unit of Dow, to customers.

The Alliance offers provides customized solutions, products, and support services for pharmaceutical product development. The portfolio will include controlled-release technologies METHOCEL CR Cellulose Ethers, ETHOCEL polymers, and POLYOX resins; and excipient technologies including AFFINISOL polymers for solubility enhancement, ENTERACT polymers for enteric tablet coatings, and DUOLITE and AMBERLITE ion exchange resins for controlled release and other applications.

The addition of new technologies into the Alliance product portfolio expands the existing relationship between Colorcon and Dow and further enables formulation and development of fast-growing pharmaceutical applications, beyond the existing controlled release scope, the companies report in a press statement.

The agreement also renews an innovation partnership, in which Colorcon and Dow collaborate on the development and commercialization of controlled-release excipients.

Source: Colorcon and The Dow Chemical Company

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content